Evaluation of combined bevacizumab plus irinotecan therapy in brain tumors using magnetic resonance imaging measures of relative cerebral blood volume
| Autor: | Kimberly R. Pechman, D. P. Bedekar, Kathleen M. Schmainda, Shekar N. Kurpad, Deborah L. Donohoe |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Pathology genetic structures medicine.diagnostic_test Bevacizumab business.industry Brain tumor Blood volume Magnetic resonance imaging medicine.disease Irinotecan Cerebral blood volume Text mining medicine Radiology Nuclear Medicine and imaging Radiology business Camptothecin medicine.drug |
| Zdroj: | Magnetic Resonance in Medicine. 68:1266-1272 |
| ISSN: | 0740-3194 |
| DOI: | 10.1002/mrm.23315 |
| Popis: | Frequently, bevacizumab is combined with chemotherapeutics such as irinotecan, motivated by studies showing improved clinical outcomes compared to historical controls. However, no systematic studies have been performed to determine if and how these drugs should be combined for optimal therapeutic response. The purpose of this study was to characterize the temporal combinations of bevacizumab and irinotecan by measuring the contrast-agent enhanced tumor volumes and relative cerebral blood volume (rCBV) using dynamic susceptibility contrast (DSC) imaging. The studies, performed in the U87 brain tumor model, show a vascular normalization window with bevacizumab monotherapy and are consistent with clinical indications of no additional benefit in the addition of irinotecan to bevacizumab therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text